MicroPharm Limited
Newcastle Emlyn, GB· latest recorded location
MicroPharm Limited is named on 6 US grants and 11 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 6
- Published applications
- 11
- Inventors
- 13
- Granted in 2026 so far
- 1
- Most recent grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 2 | 2 |
| 2020 | 0 | 0 |
| 2021 | 1 | 4 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 17 documents
Recent patents
- Clostridium difficile antigens25 Aug 2026US 12,714,742 B2
- Clostridium difficile antigens9 Dec 2025US 12,491,239 B2
- Ovine derived human TNFα polyclonal antibody composition for oral administration24 Aug 2021US 11,098,114 B2
- Filovirus therapy31 Dec 2019US 10,519,219 B2
- Clostridium difficile antigens6 Aug 2019US 10,369,206 B2
- Clostridium difficile antigens1 Jun 2023US 2023/0165949 A1
- Clostridium difficile antigens2 Dec 2021US 2021/0369830 A1
- Therapies for treating inflammatory disorders11 Nov 2021US 2021/0347876 A1
- Therapies for treating oral mucositis with polyclonal anti-tnfalpha antibodies30 Sep 2021US 2021/0301008 A1
- Therapies for treating proctitis with polyclonal anti-tnfalpha antibodies23 Sep 2021US 2021/0292403 A1
Most cited
By later US patents